Dantrials ApS

The Zelo Fase I Enhed at Dantrials ApS is concentrating on chronic airway infections, developing inhaled antimicrobial formulations to improve bacterial clearance in the lungs.

• Proof‑of‑concept evaluation of nebulised antibiotics
• Assessment of sputum bacterial load reduction
• Safety monitoring in healthy volunteers and patients

This early‑phase work aims to establish a safer, more effective treatment option for individuals with persistent bacterial colonisation, such as those with cystic fibrosis or primary ciliary dyskinesia.

Researchers are exploring innovative cell‑based therapies for knee osteoarthritis, focusing on intra‑articular delivery of engineered gingival fibroblasts to support joint repair.

• First‑in‑human safety and feasibility study
• Evaluation of joint pain and functional improvement
• Monitoring of local tissue response

The goal is to provide a regenerative alternative that could delay or reduce the need for joint replacement surgery.

Dantrials ApS maintains a strategic interest in viral infections, preparing the platform for future early‑stage studies of antiviral agents and immune‑modulating approaches.

• Exploratory safety assessments of novel antivirals
• Biomarker development for viral load monitoring
• Readiness for rapid trial activation during outbreaks

While no active trial is listed, the site’s infrastructure positions it to contribute quickly to emerging therapeutic needs in the viral disease arena.